Track topics on Twitter Track topics that are important to you
TYSONS CORNER, Va., July 23, 2015 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC) today announced that the Company's specialty pharmacy operations recorded $2.23 million in approved orders during the combined months of May and June 2015.
"Recent changes in insurance coverage and nationwide policies have attributed to a decrease in volume for the specialty pharmacy industry as a whole which has impacted our sales. As a result, management has been working diligently to expand our product and service offerings, distribution network and revenue stream in this market. ScripsAmerica has simultaneously continued to add clients and revenue in our diabetic, dispensing and wholesale divisions, which we believe will steadily contribute to an increase in shareholder value," commented Brian Ettinger, Interim CEO of ScripsAmerica.
Ettinger added, "Additionally, we would like to inform our shareholders that the company holds the filing of its 2014 annual report and subsequent 2015 financials as its top priority. ScripsAmerica has also maintained its shares authorized and outstanding at approximately 140 million as we believe in forming a strong foundation from which we can grow by preventing any potential stock dilution moving forward."
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Seal Point Consulting, LLC 888-959-7095 firstname.lastname@example.orgNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...